EFFECT OF SURGERY ON BLOOD FLOW TO BRAIN IN MOYAMOYA DISEASE
Not Applicable
- Conditions
- Health Condition 1: I675- Moyamoya disease
- Registration Number
- CTRI/2019/08/020692
- Lead Sponsor
- DEPT OF NEUROANAESTHESIA AIIMS
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot Yet Recruiting
- Sex
- Not specified
- Target Recruitment
- 0
Inclusion Criteria
All patients with angiographically diagnosed Moyamoya disease and posted for revascularisation are to be included in the study.
Exclusion Criteria
1. Refusal of consent
2. Moyamoya syndrome â?? associated with other vascular lesions of the brain, CNS
tumours, prior history of radiation for CNS tumours, Downâ??s syndrome.
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method To observe the changes in regional cerebral oxygen saturation (rSO2) following surgical revascularisation in patients with Moyamoya Disease.Timepoint: Till 24 hours postoperatively
- Secondary Outcome Measures
Name Time Method To assess long term clinical outcomes in revascularisation procedures using modified Rankin scoreTimepoint: 90 days after surgery;To assess the utility of rSO2 as a predictor of postoperative complications after revascularisation proceduresTimepoint: 24 hours after surgery;To compare the postoperative changes in rSO2 observed following different surgical methods and anaesthetic techniques usedTimepoint: 24 hours after surgery
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms underlie cerebral oxygen saturation changes post-revascularization in Moyamoya disease?
How does surgical revascularization compare to endovascular treatments for improving cerebral perfusion in Moyamoya patients?
Which biomarkers predict response to indirect bypass surgery in CTRI/2019/08/020692 Moyamoya disease trial?
What adverse events are associated with pial synangiosis in Moyamoya disease and how are they managed?
Are there adjunctive therapies like antiplatelet agents that enhance outcomes of CTRI/2019/08/020692 surgical revascularization?